Protagonist Therapeutics Inc (PTGX)
40.63
-0.41
(-1.00%)
USD |
NASDAQ |
Nov 15, 12:43
Protagonist Therapeutics Net Income (TTM): 170.85M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
Date | Value |
---|---|
September 30, 2024 | 170.85M |
June 30, 2024 | 169.95M |
March 31, 2024 | 162.11M |
December 31, 2023 | -78.96M |
September 30, 2023 | -140.48M |
June 30, 2023 | -137.61M |
March 31, 2023 | -140.19M |
December 31, 2022 | -127.39M |
September 30, 2022 | -130.11M |
June 30, 2022 | -132.68M |
March 31, 2022 | -122.48M |
December 31, 2021 | -125.55M |
September 30, 2021 | -107.53M |
June 30, 2021 | -81.49M |
March 31, 2021 | -70.07M |
December 31, 2020 | -66.15M |
September 30, 2020 | -64.76M |
June 30, 2020 | -73.41M |
Date | Value |
---|---|
March 31, 2020 | -83.16M |
December 31, 2019 | -77.19M |
September 30, 2019 | -73.55M |
June 30, 2019 | -65.88M |
March 31, 2019 | -45.37M |
December 31, 2018 | -38.92M |
September 30, 2018 | -28.11M |
June 30, 2018 | -24.20M |
March 31, 2018 | -30.52M |
December 31, 2017 | -36.96M |
September 30, 2017 | -45.15M |
June 30, 2017 | -47.41M |
March 31, 2017 | -39.53M |
December 31, 2016 | -37.18M |
September 30, 2016 | -31.42M |
June 30, 2016 | -27.79M |
March 31, 2016 | -23.91M |
December 31, 2015 | -14.86M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-140.48M
Minimum
Sep 2023
170.85M
Maximum
Sep 2024
-62.82M
Average
-82.33M
Median
Net Income (TTM) Benchmarks
Johnson & Johnson | 14.68B |
Assembly Biosciences Inc | -45.61M |
Precision BioSciences Inc | 8.623M |
Entrada Therapeutics Inc | 54.95M |
NovaBay Pharmaceuticals Inc | -10.12M |